DSM's $1.1B Martek Acquisition Comes With Potential IP Expirations
This article was originally published in The Tan Sheet
Executive Summary
Dutch ingredients giant Royal DSM N.V. incurs no incremental risk in acquiring Martek Biosciences despite the looming expiration dates for Martek's intellectual property, according to a market analyst.
You may also be interested in...
People In Brief
Erykman joins DSM as executive VP
In Brief
Prestige Brands gains from acquisitions
Interview: Health & Wellness Investment Bank PCGA Prioritizes Supplement Innovation, Quality
Investment capital has followed the flood of consumer interest in the natural health and wellness market. Partnership Capital Growth Advisors was founded as an investment bank and financial advisor in 2005 to focus precisely on the "healthy, active and sustainable living" segment.